10-QPeriod: Q1 FY2011

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2011

Filed May 10, 2011For Securities:AMGN

Summary

Amgen Inc. (AMGN) reported its first quarter results for the period ending March 30, 2011. The company appears to be in a stable financial position based on the structure of the 10-Q filing, which includes its condensed consolidated financial statements (income, balance sheet, and cash flows) and the critical Management's Discussion and Analysis (MD&A). Investors should pay close attention to the MD&A for insights into the company's operational performance, financial condition, and future outlook. Key areas of focus for investors in this filing would include revenue generation and profitability trends, cash flow from operations, and any significant developments or risks disclosed. The inclusion of Legal Proceedings and Risk Factors sections indicates potential areas of concern or areas requiring further due diligence by investors. Without the specific financial data from the statements, a detailed quantitative analysis is not possible, but the filing structure suggests a comprehensive review of the company's performance and risks is available.

Financial Highlights

52 data points
Beta

Revenue

$3.71B

82.4% Gross Margin

Net Income

$1.13B

30.4% Net Margin

EPS (Diluted)

$1.20

Total Assets

$42.71B

Cash & Equivalents

$1.27B

Free Cash Flow

$930.00M

Financial Statements
Beta
Revenue$3.71B
Gross Profit$3.05B
SG&A Expenses$1.02B
Operating Expenses$2.41B
Operating Income$1.29B
Interest Expense$135.00M
Net Income$1.13B
EPS (Basic)$1.21
EPS (Diluted)$1.20
Shares Outstanding (Basic)933.00M
Shares Outstanding (Diluted)941.00M

Key Highlights

  • 1The 10-Q filing for the quarter ending March 30, 2011, provides investors with essential financial statements, including income, balance sheet, and cash flow data.
  • 2Management's Discussion and Analysis (MD&A) is a key section for understanding operational performance, financial condition, and future outlook.
  • 3The report includes sections on Legal Proceedings and Risk Factors, which are crucial for investors to assess potential liabilities and business risks.
  • 4Amgen Inc. (AMGN) is providing a regular update on its financial health and operational status to the market.
  • 5Investors can examine revenue, expenses, assets, liabilities, and cash flow movements to gauge the company's financial trajectory.
  • 6The filing structure suggests a thorough review of the company's financial health and strategic considerations for the period.

Frequently Asked Questions

The 10-Q filing includes the Condensed Consolidated Statements of Income, which would detail revenue, cost of goods sold, operating expenses, and net income, allowing investors to assess profitability and revenue trends. The Condensed Consolidated Statements of Cash Flows would provide insights into cash generated from operations, investing activities, and financing activities.

Item 1A, Risk Factors, and Item 3, Legal Proceedings, would outline the primary risks and any ongoing legal matters that could materially impact Amgen's financial condition or results of operations. Investors should carefully review these sections for potential headwinds.

The most critical section for this information is Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations. This section provides management's narrative on the company's performance, liquidity, capital resources, and future expectations.

Item 6, Exhibits, typically contains supporting documents filed with the SEC. For investors, this might include material contracts, articles of incorporation, or other agreements that provide further context to the company's business and financial dealings.